Center for Cell and Gene Therapy, Baylor College of Medicine
116
14
39
52
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
19.8%
23 terminated/withdrawn out of 116 trials
69.3%
-17.3% vs industry average
0%
0 trials in Phase 3/4
44%
23 of 52 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (116)
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
Role: collaborator
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Role: collaborator
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Role: collaborator
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Role: collaborator
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Role: collaborator
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Role: collaborator
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Role: collaborator
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Role: collaborator
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Role: collaborator
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Role: collaborator
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
Role: collaborator
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Role: collaborator
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
Role: collaborator
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Role: collaborator
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
Role: collaborator
Vitamin C With Steroids for Gastrointestinal GVHD
Role: collaborator
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Role: collaborator
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
Role: collaborator
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Role: collaborator
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Role: collaborator